Skip to main content
Top
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study

Authors: Melissa J Newton, Sandi C Hayes, Monika Janda, Penelope M Webb, Andreas Obermair, Elizabeth G Eakin, David Wyld, Louisa G Gordon, Vanessa L Beesley

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Exercise interventions during adjuvant cancer therapy have been shown to increase functional capacity, relieve fatigue and distress and may assist rates of chemotherapy completion. These studies have been limited to breast, gastric and mixed cancer groups and it is not yet known if a similar intervention is even feasible among women with ovarian cancer. We aimed to assess safety, feasibility and potential effect of a walking intervention in women undergoing chemotherapy for ovarian cancer.

Methods

Women newly diagnosed with ovarian cancer were recruited to participate in an individualised walking intervention throughout chemotherapy and were assessed pre- and post-intervention. Feasibility measures included session adherence, compliance with exercise physiologist prescribed walking targets and self-reported program acceptability. Changes in objective physical functioning (6-minute walk test), self-reported distress (Hospital Anxiety and Depression Scale), symptoms (Memorial Symptom Assessment Scale - Physical) and quality of life (Functional Assessment of Cancer Therapy - Ovarian) were calculated, and chemotherapy completion and adverse intervention effects recorded.

Results

Seventeen women were enrolled (63% recruitment rate). Mean age was 60 years (SD = 8 years), 88% were diagnosed with FIGO stage III or IV disease, 14 women underwent adjuvant and three neo-adjuvant chemotherapy. On average, women adhered to > 80% of their intervention sessions and complied with 76% of their walking targets, with the majority walking four days a week at moderate intensity for 30 minutes per session. Meaningful improvements were found in physical functioning, physical symptoms, physical well-being and ovarian cancer-specific quality of life. Most women (76%) completed ≥85% of their planned chemotherapy dose. There were no withdrawals or serious adverse events and all women reported the program as being helpful.

Conclusions

These positive preliminary results suggest that this walking intervention for women receiving chemotherapy for ovarian cancer is safe, feasible and acceptable and could be used in development of future work.

Trial registration

Appendix
Available only for authorised users
Literature
1.
go back to reference Australian Institute of Health and Welfare (AIHW) & Australasian Association of Cancer Registries (AACR): Cancer in Australia 2000. 2003, Canberra: AIHW (Cancer Series no 23), AIHW Cat. No. CAN 18 Australian Institute of Health and Welfare (AIHW) & Australasian Association of Cancer Registries (AACR): Cancer in Australia 2000. 2003, Canberra: AIHW (Cancer Series no 23), AIHW Cat. No. CAN 18
2.
go back to reference Quasthoff S, Hartung H: Chemotherapy-induced peripheral neuropathy. J Neurol. 2002, 249: 9-17. 10.1007/PL00007853.CrossRefPubMed Quasthoff S, Hartung H: Chemotherapy-induced peripheral neuropathy. J Neurol. 2002, 249: 9-17. 10.1007/PL00007853.CrossRefPubMed
3.
go back to reference Gordon LG, Scuffham PA, Beesley VL, Green AC, DeFazio A, Wyld DK, Clavarino AM, Australian Ovarian Cancer Study Group, Webb PM: Outcomes and related medical costs for women with ovarian cancer in Australia: a patient-level analysis over 21/2 years. Int J Gynecol Cancer. 2010, 20: 757-765. 10.1111/IGC.0b013e3181dbd13f.CrossRefPubMed Gordon LG, Scuffham PA, Beesley VL, Green AC, DeFazio A, Wyld DK, Clavarino AM, Australian Ovarian Cancer Study Group, Webb PM: Outcomes and related medical costs for women with ovarian cancer in Australia: a patient-level analysis over 21/2 years. Int J Gynecol Cancer. 2010, 20: 757-765. 10.1111/IGC.0b013e3181dbd13f.CrossRefPubMed
4.
go back to reference Schwartz A: Physical activity after a cancer diagnosis: psychosocial outcomes. Cancer Invest. 2004, 22 (1): 82-92. 10.1081/CNV-120027582.CrossRefPubMed Schwartz A: Physical activity after a cancer diagnosis: psychosocial outcomes. Cancer Invest. 2004, 22 (1): 82-92. 10.1081/CNV-120027582.CrossRefPubMed
5.
go back to reference Olsen CM, Bain CJ, Jordan S, Nagle C, Green A, Whiteman D, Webb P, Australian Cancer Study (Ovarian Cancer) and Australian Ovarian Cancer Study Group: Recreational Physical Activity and Epithelial Ovarian Cancer: A Case-Control Study, Systematic Review, and Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2007, 16 (11): 2321-2330. 10.1158/1055-9965.EPI-07-0566.CrossRefPubMed Olsen CM, Bain CJ, Jordan S, Nagle C, Green A, Whiteman D, Webb P, Australian Cancer Study (Ovarian Cancer) and Australian Ovarian Cancer Study Group: Recreational Physical Activity and Epithelial Ovarian Cancer: A Case-Control Study, Systematic Review, and Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2007, 16 (11): 2321-2330. 10.1158/1055-9965.EPI-07-0566.CrossRefPubMed
6.
go back to reference Bodurka-Bevers D, Basen-Engquist K, Carmack C, Fitzgerald M, Wolf J, de Moor C, Gershenson D: Depression, Anxiety, and Quality of Life in Patients with Epithelial Ovarian Cancer. Gynecol Oncol. 2000, 78: 302-308. 10.1006/gyno.2000.5908.CrossRefPubMed Bodurka-Bevers D, Basen-Engquist K, Carmack C, Fitzgerald M, Wolf J, de Moor C, Gershenson D: Depression, Anxiety, and Quality of Life in Patients with Epithelial Ovarian Cancer. Gynecol Oncol. 2000, 78: 302-308. 10.1006/gyno.2000.5908.CrossRefPubMed
7.
go back to reference Wenzel L, Huang H, Armstrong D, Walker J, Cella D: Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007, 25: 437-443. 10.1200/JCO.2006.07.3494.CrossRefPubMed Wenzel L, Huang H, Armstrong D, Walker J, Cella D: Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007, 25: 437-443. 10.1200/JCO.2006.07.3494.CrossRefPubMed
8.
go back to reference Oken MM, Creech RH, Tormey DC, Horton J, Davis T, McFadden ET, Carbone P: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982, 5: 649-655. 10.1097/00000421-198212000-00014.CrossRefPubMed Oken MM, Creech RH, Tormey DC, Horton J, Davis T, McFadden ET, Carbone P: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982, 5: 649-655. 10.1097/00000421-198212000-00014.CrossRefPubMed
9.
go back to reference Markman M, Bundy B, Alberts D, Clark-Pearson DL, Carson LF, Wadler S, Sickel J: Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001, 19 (4): 1001-1007.PubMed Markman M, Bundy B, Alberts D, Clark-Pearson DL, Carson LF, Wadler S, Sickel J: Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001, 19 (4): 1001-1007.PubMed
10.
go back to reference Armstrong DK, Bundy B, Wenzel L, Huang H, Baergen R, Lele S, Copeland L, Walker J, Burger R, for the Gynecologic Oncology Group: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Eng J Med. 2006, 354 (1): 34-43. 10.1056/NEJMoa052985.CrossRefPubMed Armstrong DK, Bundy B, Wenzel L, Huang H, Baergen R, Lele S, Copeland L, Walker J, Burger R, for the Gynecologic Oncology Group: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Eng J Med. 2006, 354 (1): 34-43. 10.1056/NEJMoa052985.CrossRefPubMed
11.
go back to reference Hirria A, Leung D, Trainor K, Borgen P, Norton L, Hudis C: Factor influencing treatment patterns of breast cancer patients age 75 and older. Crit Rev Oncol Hematol. 2003, 46: 121-126. 10.1016/S1040-8428(02)00133-6.CrossRef Hirria A, Leung D, Trainor K, Borgen P, Norton L, Hudis C: Factor influencing treatment patterns of breast cancer patients age 75 and older. Crit Rev Oncol Hematol. 2003, 46: 121-126. 10.1016/S1040-8428(02)00133-6.CrossRef
12.
go back to reference Law CC, Fu YT: Postoperative adjuvant 5-Fluororuacil plus levamisole chemotherapy for stage III colon carcinoma: 7-year experience in a single institution. J Hong Kong College Rad. 2002, 5: 97-104. Law CC, Fu YT: Postoperative adjuvant 5-Fluororuacil plus levamisole chemotherapy for stage III colon carcinoma: 7-year experience in a single institution. J Hong Kong College Rad. 2002, 5: 97-104.
13.
go back to reference D'hondt R, Paridaens R, Wildiers H, Pauwelyn K, Thomas J, Dumez H, Van Oosterom A: Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. Anticancer Drug. 2004, 15: 341-346. 10.1097/00001813-200404000-00005.CrossRef D'hondt R, Paridaens R, Wildiers H, Pauwelyn K, Thomas J, Dumez H, Van Oosterom A: Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. Anticancer Drug. 2004, 15: 341-346. 10.1097/00001813-200404000-00005.CrossRef
14.
go back to reference Speck RM, Courneya KS, Mâsse LC, Duval S, Schmitz KH: An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv. 2010, 4: 87-100. 10.1007/s11764-009-0110-5.CrossRefPubMed Speck RM, Courneya KS, Mâsse LC, Duval S, Schmitz KH: An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv. 2010, 4: 87-100. 10.1007/s11764-009-0110-5.CrossRefPubMed
15.
go back to reference Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid R, Friedenreich C, Ladha A, Proulx C, Vallance J, Lane K, Yasui Y, McKenzie D: Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol. 2007, 25: 4396-4404. 10.1200/JCO.2006.08.2024.CrossRefPubMed Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid R, Friedenreich C, Ladha A, Proulx C, Vallance J, Lane K, Yasui Y, McKenzie D: Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol. 2007, 25: 4396-4404. 10.1200/JCO.2006.08.2024.CrossRefPubMed
16.
go back to reference Hayes SC, Spence RR, Galvao DA, Newton R: Australian Association for Exercise and Sport Science position stand: optimising cancer outcomes through exercise. J Sci Med Sport. 2009, 12: 428-434. 10.1016/j.jsams.2009.03.002.CrossRefPubMed Hayes SC, Spence RR, Galvao DA, Newton R: Australian Association for Exercise and Sport Science position stand: optimising cancer outcomes through exercise. J Sci Med Sport. 2009, 12: 428-434. 10.1016/j.jsams.2009.03.002.CrossRefPubMed
17.
go back to reference Von Gruenigen V, Frasure H, Kavanagh M, Lerner E, Waggoner SE, Courneya KS: Feasibility of a lifestyle intervention for ovarian cancer patients receiving adjuvant chemotherapy. Gynecol Oncol. 2011, Von Gruenigen V, Frasure H, Kavanagh M, Lerner E, Waggoner SE, Courneya KS: Feasibility of a lifestyle intervention for ovarian cancer patients receiving adjuvant chemotherapy. Gynecol Oncol. 2011,
18.
go back to reference ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002, 166: 111-117. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002, 166: 111-117.
19.
go back to reference Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983, 67 (6): 361-370. 10.1111/j.1600-0447.1983.tb09716.x.CrossRefPubMed Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983, 67 (6): 361-370. 10.1111/j.1600-0447.1983.tb09716.x.CrossRefPubMed
20.
go back to reference Chang V, Hwang S, Feuerman M, Kasimis B, Thaler H: The Memorial Symptom Assessment Scale Short Form (MSAS-SF) Validity and Reliability. Cancer. 2000, 89: 1162-1171. 10.1002/1097-0142(20000901)89:5<1162::AID-CNCR26>3.0.CO;2-Y.CrossRefPubMed Chang V, Hwang S, Feuerman M, Kasimis B, Thaler H: The Memorial Symptom Assessment Scale Short Form (MSAS-SF) Validity and Reliability. Cancer. 2000, 89: 1162-1171. 10.1002/1097-0142(20000901)89:5<1162::AID-CNCR26>3.0.CO;2-Y.CrossRefPubMed
21.
go back to reference Basen-Engquist K, Bodurka-Bevers D, Fitzgerald M, Webster K, Cella D, Hu S, Gershenson D: Reliability and validity of the functional assessment of cancer therapy - Ovarian. J Clin Oncol. 2001, 19: 1809-1817.PubMed Basen-Engquist K, Bodurka-Bevers D, Fitzgerald M, Webster K, Cella D, Hu S, Gershenson D: Reliability and validity of the functional assessment of cancer therapy - Ovarian. J Clin Oncol. 2001, 19: 1809-1817.PubMed
22.
go back to reference Terada Y, Nakamae H, Aimoto R, Kanashima H, Sakamoto E, Aimoto M, Inoue E, Koh H, Nakane T, Takeoka Y, Ohsawa M, Koh KR, Yamane T, Nakao Y, Ohta K, Mugitani A, Teshima H, Hino M: Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. J Exper Clin Can Res. 2009, 28: 116-10.1186/1756-9966-28-116.CrossRef Terada Y, Nakamae H, Aimoto R, Kanashima H, Sakamoto E, Aimoto M, Inoue E, Koh H, Nakane T, Takeoka Y, Ohsawa M, Koh KR, Yamane T, Nakao Y, Ohta K, Mugitani A, Teshima H, Hino M: Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. J Exper Clin Can Res. 2009, 28: 116-10.1186/1756-9966-28-116.CrossRef
23.
go back to reference Rasekaba T, Lee AL, Naughton MT, Williams TJ, Holland AE: The six-minute walk test: a useful metric for the cardiopulmonary patient. Intern Med J. 2009, 39 (8): 495-501. 10.1111/j.1445-5994.2008.01880.x.CrossRefPubMed Rasekaba T, Lee AL, Naughton MT, Williams TJ, Holland AE: The six-minute walk test: a useful metric for the cardiopulmonary patient. Intern Med J. 2009, 39 (8): 495-501. 10.1111/j.1445-5994.2008.01880.x.CrossRefPubMed
24.
go back to reference Puhan M, Frey M, Büchi S, Schünemann H: The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcome. 2008, 6: 46-10.1186/1477-7525-6-46.CrossRef Puhan M, Frey M, Büchi S, Schünemann H: The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcome. 2008, 6: 46-10.1186/1477-7525-6-46.CrossRef
25.
go back to reference Walker P: Which symptoms are prevalent in patients with recurrent ovarian cancer?. J Clin Oncol. 2008, 26 (No 15S): 20689- Walker P: Which symptoms are prevalent in patients with recurrent ovarian cancer?. J Clin Oncol. 2008, 26 (No 15S): 20689-
26.
go back to reference Sloan JA, Cella D, Hays RD: Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol. 2005, 58 (12): 1217-1219. 10.1016/j.jclinepi.2005.07.009.CrossRefPubMed Sloan JA, Cella D, Hays RD: Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol. 2005, 58 (12): 1217-1219. 10.1016/j.jclinepi.2005.07.009.CrossRefPubMed
27.
go back to reference Queensland Centre for Gynecological Cancer. Outcome data statistical report. 2008 Queensland Centre for Gynecological Cancer. Outcome data statistical report. 2008
28.
go back to reference Courneya KS, Friedenreich CM, Sela RA, Quinney HA, Rhodes RE, Handman M: The group psychotherapy and home-based physical exercise (Group-Hope) trail in cancer survivors: Physical fitness and quality of life outcomes. Psycho-oncology. 2003, 12: 357-374. 10.1002/pon.658.CrossRefPubMed Courneya KS, Friedenreich CM, Sela RA, Quinney HA, Rhodes RE, Handman M: The group psychotherapy and home-based physical exercise (Group-Hope) trail in cancer survivors: Physical fitness and quality of life outcomes. Psycho-oncology. 2003, 12: 357-374. 10.1002/pon.658.CrossRefPubMed
29.
go back to reference Stevinson C, Capstick V, Schepansky A, Tonkin K, Vallance JK, Ladha AB, Steed H, Faught W, Courneya KS: Physical activity preferences of ovarian cancer survivors. Psycho-oncology. 2009, 18 (4): 422-428. 10.1002/pon.1396.CrossRefPubMed Stevinson C, Capstick V, Schepansky A, Tonkin K, Vallance JK, Ladha AB, Steed H, Faught W, Courneya KS: Physical activity preferences of ovarian cancer survivors. Psycho-oncology. 2009, 18 (4): 422-428. 10.1002/pon.1396.CrossRefPubMed
30.
go back to reference Joly F, Vardy J, Pintilie M, Tannock I: Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol. 2007, 18: 1935-1942. 10.1093/annonc/mdm121.CrossRefPubMed Joly F, Vardy J, Pintilie M, Tannock I: Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol. 2007, 18: 1935-1942. 10.1093/annonc/mdm121.CrossRefPubMed
Metadata
Title
Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: a pilot study
Authors
Melissa J Newton
Sandi C Hayes
Monika Janda
Penelope M Webb
Andreas Obermair
Elizabeth G Eakin
David Wyld
Louisa G Gordon
Vanessa L Beesley
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-389

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine